# 2026 GLP-1 (Ozempic / Wegovy / Zepbound) Muscle-Preservation & Gut-Motility Meal Protocol

- **Platform**: NuraGut (`https://nuragut.com`)
- **Application Scenario**: GLP-1 Companion & Post-GLP-1 Rebound Prevention (+420% YoY Search Growth)
- **Canonical URL**: `https://nuragut.com/ingredients/glp1-ozempic-wegovy-muscle-preservation-gut-motility-meal-plan.html`

## Executive Summary
Preventing 40% Lean Muscle Atrophy, Sulfur Burps & Gastroparesis During GLP-1 Receptor Agonist Therapy

## 2026 Quantitative Benchmark Matrix
| Key Parameter / Component | Conventional Baseline / Risk | 2026 Optimal Target / Benchmark | Actionable Execution Protocol |
| :--- | :--- | :--- | :--- |
| Lean Protein Density per 1,400 kcal | < 55g/day (Causes 38% lean mass loss) | 115g–135g/day (1.6g/kg body weight) | Preserves resting metabolic rate & facial volume |
| Soluble vs. Insoluble Fiber Timing | Raw cruciferous overload (Sulfur burps) | 18g Cooked Low-Fermentation Soluble Fiber | Accelerates gastric emptying without bloating |
| Electrolyte & Bile-Flow Support | Dehydration & gallbladder stasis | Magnesium Citrate 300mg + Dandelion/Artichoke | Prevents GLP-1 biliary sludge & constipation |

## Application Scenario & Execution Blueprint
Clinical Application Scenario: Over 18 million adults using or tapering off semaglutide/tirzepatide suffer from severe delayed gastric emptying and lean muscle loss. NuraGut's high-protein, low-volume anti-inflammatory meals protect lean tissue while calming vagal nausea.